We found that TNFAIP3 serum level decrements are associated with the onset of a relapse in individual MOG-AAD patients and thus has significant potential as a biomarker and therapeutic target for MOG-AAD and other autoimmune diseases. The gene discussed is MOG; the disease is autoimmune disease.